Bicycle Therapeutics
Cambridge, United States · Biotechnology, Health Care, Pharmaceutical
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their
Key facts
- Headquarters
- Cambridge, United States
- Employees
- 316
- Industries
- Biotechnology, Health Care, Pharmaceutical
- Status
- Public (BCYC)
- Website
- www.bicycletherapeutics.com
- Company page
Recent activity at Bicycle Therapeutics
- : SEC 8-K (5.02): On August 18, 2026, Charles Swanton resigned from his position as a Class II director on the Board of Directors of Bicycle Therapeutics plc. His departure may have implications for the governance and strategic direction of the company, as board composition is critical to decision-making processes. The Company will need to address this vacancy and potentially seek a replacement to ensure continued oversight and compliance with corporate governance standards.
- : SEC 8-K (8.01): On May 21, 2026, Bicycle Therapeutics plc announced the release of initial data from the Duravelo-2 clinical trial for metastatic urothelial cancer at the 2026 ASCO Annual Meeting. This press release is considered a significant event for the company as it highlights advancements in their oncology pipeline. The announcement may have strategic implications for future clinical outcomes and investor perceptions. The data could influence stock performance and attract further investments into ongoing clinical studies.
- : SEC 8-K (8.01): On April 20, 2026, Bicycle Therapeutics plc issued a press release providing updates on its nuzefatide pevedotin program and the Company's EphA2 pipeline. This update is significant as it highlights ongoing developments in their therapeutic programs, potentially affecting their strategic direction and market position. The press release is attached as Exhibit 99.1, indicating the company's commitment to keep investors informed about key advancements in its drug development initiatives.
- : SEC 8-K (5.02):
- : Bicycle Therapeutics Appoints Travis Thompson as Chief Executive Officer
- : SEC 8-K (5.02): On January 29, 2026, Bicycle Therapeutics plc appointed Travis Thompson as Chief Financial Officer, succeeding Alethia Young, who has left her role on the same date. Travis Thompson, previously the Senior Vice President and Chief Accounting Officer since June 2023, will receive a base salary of $500,000, and is eligible for a target annual cash performance bonus of 50% of his base salary. He will also receive options to purchase 58,000 shares as part of the Company's equity incentive plan. Ms. Young will remain with the Company for three months in an interim capacity and will serve as an advisor thereafter under a Separation Agreement. This leadership transition is expected to strengthen the financial leadership amid ongoing company growth.
- : SEC 8-K (8.01): On January 12, 2026, Bicycle Therapeutics plc issued a press release detailing its recent accomplishments and strategic priorities for the year 2026. The filing serves to inform shareholders about the Company's future direction and objectives. This communication is significant as it outlines the company's planned initiatives and focuses for the upcoming year, which may impact market perception and share value. The press release is included as Exhibit 99.1 within the report.
- : Bicycle Therapeutics forms strategic partnerships to enhance its radiopharmaceutical pipeline and secure reprocessed uranium supply.
- : Bicycle Therapeutics to Present Zelenectide Pevedotin Data at the 2024 San Antonio Breast Cancer Symposium.
- : Bicycle Therapeutics Advances its Clinical Pipeline and Reports Third Quarter 2024 Financial Results
Bicycle Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Jun 2024 | Venture | $555.5M |
| May 2024 | Post-IPO Equity | $555.0M |
Leadership
- Travis Thompson, Chief Executive Officer
- Kevin Lee, Chief Executive Officer
Verified email and direct lines for Bicycle Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Bicycle Therapeutics files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Bicycle Therapeutics in the news
- Bicycle Therapeutics plc (BCYC) stock price, news, quote and history - Yahoo Finance UK (Oct 30, 2026)
- Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline - Business Wire (Dec 16, 2025)
- How can we target emerging oligonucleotide therapies for success? - drugdiscoverytrends.com (Nov 29, 2022)
- Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 - Business Wire (Apr 20, 2026)
Companies similar to Bicycle Therapeutics
- Esperion Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- ABC Pharmaceuticals · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Nurix Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Ryvu Therapeutics · Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Vectura Group Limited · Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Bicycle Therapeutics: questions and answers
What does Bicycle Therapeutics do?
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company that is harnessing the power of bicyclic peptides and leveraging Nobel Prize-winning science to develop a new and differentiated class of medicines to treat cancer and other diseases. Bicycle® molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their
Where is Bicycle Therapeutics headquartered?
Bicycle Therapeutics is headquartered in Cambridge, United States.
How many employees does Bicycle Therapeutics have?
Bicycle Therapeutics has about 316 employees.
Has Bicycle Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Bicycle Therapeutics. The most recent, $555.5M, was in Jun 2024.
Who leads Bicycle Therapeutics?
Travis Thompson is a Chief Executive Officer at Bicycle Therapeutics.
What is the latest news on Bicycle Therapeutics?
On Aug 18, 2026, SEC 8-K (5.02): On August 18, 2026, Charles Swanton resigned from his position as a Class II director on the Board of Directors of Bicycle Therapeutics plc. His departure may have implications for the governance and strategic direction of the company, as board composition is critical to decision-mak
Is Bicycle Therapeutics a public company?
Yes. Bicycle Therapeutics is publicly traded under the ticker BCYC.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy